NF-κB signaling, liver disease and hepatoprotective agents

Oncogene

Volumn 27, Issue 48, 2008, Pages 6228-6244

  Sun, B ^a   Karin, M ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Hepatitis; Hepatocellular carcinoma; Liver disease; NF B

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBROTIC AGENT; ANTIOXIDANT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CURCUMIN; EPICATECHIN; EPICATECHIN 3 GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GLUCOCORTICOID; GUAIACOL; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; LIVER PROTECTIVE AGENT; LUPEOL; LYCOPENE; OLIGONUCLEOTIDE; POLYPHENOL; PROTEASOME INHIBITOR; RALOXIFENE; RESVERATROL; SALAZOSULFAPYRIDINE; SALINOSPORAMIDE A; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SMALL INTERFERING RNA; TAMOXIFEN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL LIVER DISEASE; CANCER PREVENTION; CANCER RESISTANCE; CHEMOPROPHYLAXIS; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HELICOBACTER; HELICOBACTER INFECTION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DEVELOPMENT; LIVER DISEASE; LIVER FIBROSIS; LIVER PROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

HELICOBACTER; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

HUMANS; LIVER DISEASES; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 54249125424     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.300     Document Type: Review

References (175)

1. Alderton WK, Cooper CE, Knowles RG. (2001). Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615.
2. Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC et al. (1999). Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 397: 176-180.
3. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. (2006). Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 43: 335-344.
4. Andersen LP. (2001). New Helicobacter species in humans. Dig Dis 19: 112-115.
5. Atabay HI, Corry JE, On SL. (1998). Identification of unusual Campylobacter-like isolates from poultry products as Helicobacter pullorum. J Appl Microbiol 84: 1017-1024.
6. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR et al. (2006). Curcumin inhibits hypoxia-induced angiogenesis via downregulation of HIF-1. Oncol Rep 15: 1557-1562.
7. Bataller R, Brenner DA. (2005). Liver fibrosis. J Clin Invest 115: 209-218.
8. Bautista AP. (2002). Chronic alcohol intoxication primes Kupffer cells and endothelial cells for enhanced CC-chemokine production and concomitantly suppresses phagocytosis and chemotaxis. Front Biosci 7: a117-a125.
9. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. (1995). Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376: 167-170.
10. Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L et al. (2002). Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16: 267-269.
11. Bernier M, Kwon YK, Pandey SK, Zhu TN, Zhao RJ, Maciuk A et al. (2006). Binding of manumycin A inhibits IkappaB kinase beta activity. J Biol Chem 281: 2551-2561.
12. Bogdan C. (2001). Nitric oxide and the immune response. Nat Immunol 2: 907-916.
13. Bonizzi G, Karin M. (2004). Thetwo NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
14. Bonnard M, Mirtsos C, Suzuki S, Graham K, Huang J, Ng M et al. (2000). Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. EMBO J 19: 4976-4985.
15. Bose S, Banerjee AK. (2003). Innate immune response against nonsegmented negative strand RNA viruses. J Interferon Cytokine Res 23: 401-412.
16. Bose S, Kar N, Maitra R, DiDonato JA, Banerjee AK. (2003). Temporal activation of NF-kappaB regulates an interferon-independent innate antiviral response against cytoplasmic RNA viruses. Proc Natl Acad Sci USA 100: 10890-10895.
17. Cervello M, Giannitrapani L, La Rosa M, Notarbartolo M, Labbozzetta M, Poma P et al. (2004). Induction of apoptosis by the proteasome inhibitor MG132 in human HCC cells: Possible correlation with specific caspase-dependent cleavage of beta-catenin and inhibition of beta-catenin-mediated transactivation. Int J Mol Med 13: 741-748.
18. Chaisson ML, Brooling JT, Ladiges W, Tsai S, Fausto N. (2002). Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest 110: 193-202.
19. Chang CS, Huang SM, Lin HH, Wu CC, Wang CJ. (2007). Different expression of apoptotic proteins between HBV-infected and non-HBV-infected hepatocellular carcinoma. Hepatogastroenterology 54: 2061-2068.
20. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K et al. (2006). The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124: 601-613.
21. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. (2007). Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13: 851-856.
22. Chen D, Milacic V, Chen MS, Wan SB, Lam WH, Huo C et al. (2008a). Tea polyphenols, their biological effects and potential molecular targets. Histol Histopathol 23: 487-496.
23. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. (2003). The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 9: 575-581.
24. Chen Y, Cheng G, Mahato RI. (2008b). RNAi for treating hepatitis B viral infection. Pharm Res 25: 72-86.
25. Cheng Y, Ping J, Xu LM. (2007). Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells. Chin Med J (Engl) 120: 794-801.
26. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. (2006). Antifibrotic effects of thalidomide on hepatic stellate cells and dimethylnitrosamine- intoxicated rats. J Biomed Sci 13: 403-418.
27. Chuang SE, Cheng AL, Lin JK, Kuo ML. (2000). Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 38: 991-995.
28. Claudio E, Brown K, Park S, Wang H, Siebenlist U. (2002). BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3: 958-965.
29. Cooper A, Tal G, Lider O, Shaul Y. (2005). Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol 175: 3165-3176.
30. Coornaert B, Baens M, Heyninck K, Bekaert T, Haegman M, Staal J et al. (2008). T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat Immunol 9: 263-271.
31. Crispe IN. (2003). Hepatic T cells and liver tolerance. Nat Rev Immunol 3: 51-62.
32. Diao J, Garces R, Richardson CD. (2001). X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev 12: 189-205.
33. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. (1997). A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388: 548-554.
34. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van DePutte LB et al. (1998). Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073.
35. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M et al. (2003). Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112: 181-192.
36. Elsharkawy AM, Mann DA. (2007). Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46: 590-597.
37. Elsharkawy AM, Oakley F, Mann DA. (2005). The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10: 927-939.
38. Elsharkawy AM, Wright MC, Hay RT, Arthur MJ, Hughes T, Bahr MJ et al. (1999). Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology 30: 761-769.
39. Fan C, Li Q, Zhang Y, Liu X, Luo M, Abbott D et al. (2004). IkappaBalpha and IkappaBbeta possess injury context-specific functions that uniquely influence hepatic NF-kappaB induction and inflammation. J Clin Invest 113: 746-755.
40. Farinati F, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M et al. (2007). Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat 14: 821-829.
41. Fox JG, Dewhirst FE, Tully JG, Paster BJ, Yan L, Taylor NS et al. (1994). Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol 32: 1238-1245.
42. Fox JG, Yan LL, Dewhirst FE, Paster BJ, Shames B, Murphy JC et al. (1995). Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mice. J Clin Microbiol 33: 445-454.
43. Gao B, Jeong WI, Tian Z. (2008). Liver: An organ with predominant innate immunity. Hepatology 47: 729-736.
44. Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H et al. (1999). Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 162: 4928-4937.
45. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W et al. (2006). Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 25: 6781-6799.
46. Ghosh S, Karin M. (2002). Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl): S81-S96.
47. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C et al. (2007). NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130: 918-931.
48. Hacker H, Karin M. (2006). Regulation and function of IKK and IKK-related kinases. Sci STKE 2006: re13.
49. Hayden MS, West AP, Ghosh S. (2006). SnapShot: NF-kappaB signaling pathways. Cell 127: 1286-1287.
50. Hegewisch-Becker S, Sterneck M, Schubert U, Rogiers X, Guerciolini R, Pierce JE et al. (2004). Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 22(14S): 4089.
51. Helmberg A, Auphan N, Caelles C, Karin M. (1995). Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 14: 452-460.
52. Hemming AW, Cattral MS, Reed AI. (2001). Liver transplantation for hepatocellular carcinoma. Ann Surg 233: 652-659.
53. Hildt E, Hofschneider PH. (1998). The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Recent Results Cancer Res 154: 315-329.
54. Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R. (2003). Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann N Y Acad Sci 1010: 237-248.
55. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86-90.
56. Hopkins RJ, Girardi LS, Turney EA. (1996). Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 110: 1244-1252.
57. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y et al. (1999). Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162: 3749-3752.
58. Hu KQ. (2008). Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol 103: 1824-1833.
59. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M et al. (1999). Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284: 316-320.
60. Huang IC, Chien CY, Huang CR, Lo SJ. (2006). Induction of hepatitis D virus large antigen translocation to the cytoplasm by hepatitis B virus surface antigens correlates with endoplasmic reticulum stress and NF-kappaB activation. J Gen Virol 87: 1715-1723.
61. Hurgin V, Novick D, Werman A, Dinarello CA, Rubinstein M. (2007). Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. Proc Natl Acad Sci USA 104: 5044-5049.
62. Hwang ESLH. (2006). Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK-Hep1 human hepatoma cells. Exp Biol Med (Maywood) 231: 322-327.
63. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S et al. (1998). Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102: 538-549.
64. Ishikawa T, Ando T, Obayashi H, Nakabe N, Okita M, Isozaki Y et al. (2008). Helicobacter pylori isolated from a patient with Menetrier's disease increases hepatocyte growth factor mRNA expression in gastric fibroblasts: comparison with helicobacter pylori isolated from other gastric diseases. Dig Dis Sci 53: 1785-1791.
65. Ito K, Yamaoka Y, Ota H, El-Zimaity H, Graham DY. (2008). Adherence, internalization, and persistence of helicobacter pylori in hepatocytes. Dig Dis Sci 53: 2541-2549.
66. Jaiswal M, LaRusso NF, Gores GJ. (2001). Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 281: G626-G634.
67. Johnson CL, Owen DM, Gale Jr M. (2007). Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense. J Biol Chem 282: 10792-10803.
68. Joo M, Hahn YS, Kwon M, Sadikot RT, Blackwell TS, Christman JW. (2005). Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. J Virol 79: 7648-7657.
69. Joshi-BarveS, Barve SS, Butt W, Klein J, McClain CJ. (2003). Inhibition of proteasome function leads to NF-kappaB-independent IL-8 expression in human hepatocytes. Hepatology 38: 1178-1187.
70. Kalaitzidis D, Gilmore TD. (2005). Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 16: 46-52.
71. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. (2005). Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661.
72. Karin M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
73. Karin M, Yamamoto Y, Wang QM. (2004). The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3: 17-26.
74. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. (1999). Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115-122.
75. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S et al. (2001). Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 167: 5887-5894.
76. Kayano K, Okita K. (2000). Does IL-6 regulate liver fibrosis/cirrhosis directly and indirectly? J Gastroenterol 35: 250-251.
77. Khan N, Afaq F, Mukhtar H. (2008). Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510.
78. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E et al. (2002). Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347: 185-192.
79. Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. (2000). Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol 33: 49-58.
80. Lawrence T, Hageman T, Balkwill F. (2007). Cancer. Sex, cytokines, and cancer. Science 317: 51-52.
81. Lazarus DD, Kambayashi T, Yato-Kioka M, Baumann H, Jacob CO, Strassmann G. (1997). Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury. Int J Immunopharmacol 19: 49-58.
82. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. (1999a). Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284: 321-325.
83. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M et al. (1999b). The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189: 1839-1845.
84. Liang MC, Bardhan S, Li C, Pace EA, Porco Jr JA, Gilmore TD. (2003). Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinase. Mol Pharmacol 64: 123-131.
85. Lin A, Karin M. (2003). NF-kappaB in cancer: a marked target. Semin Cancer Biol 13: 107-114.
86. Luedde T, Assmus U, Wustefeld T, Meyer zu Vilsendorf A, Roskams T, Schmidt-Supprian M et al. (2005). Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 115: 849-859.
87. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R et al. (2007). Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11: 119-132.
88. Maaroos HI, Vorobjova T, Sipponen P, Tammur R, Uibo R, Wadstrom T et al. (1999). An 18-year follow-up study of chronic gastritis and Helicobacter pylori association of CagA positivity with development of atrophy and activity of gastritis. Scand J Gastroenterol 34: 864-869.
89. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M. (2003). IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19: 725-737.
90. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. (2005). IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121: 977-990.
91. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. (2007). Interferon: cellular executioner or white knight? Curr Med Chem 14: 1279-1289.
92. Makris C, Godfrey VL, Krahn-Senftleben G, Takahashi T, Roberts JL, Schwarz T et al. (2000). Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell 5: 969-979.
93. Malmgaard L. (2004). Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 24: 439-454.
94. Mann EA, Stanford S, Sherman KE. (2006). Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation. Virus Res 121: 51-57.
95. Mannick EE, Bravo LE, Zarama G, Realpe JL, Zhang XJ, Ruiz B et al. (1996). Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res 56: 3238-3243.
96. Marino M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR et al. (2005). Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 28: 280-284.
97. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. (2000). Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289: 1550-1554.
98. Micheau O, Tschopp J. (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114: 181-190.
99. Mukherjee S, Sorrell MF. (2008). Controversies in liver transplantation for hepatitis C. Gastroenterology 134: 1777-1788.
100. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al. (2007). Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124.
101. Oakley F, Trim N, Constandinou CM, Ye W, Gray AM, Frantz G et al. (2003). Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol 163: 1849-1858.
102. Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A et al. (2006). Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 69: 1615-1623.
103. Osada S, Saji S, Kuno T. (2004). Clinical significanceof combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol 85: 48-54.
104. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N et al. (1991). Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325: 1127-1131.
105. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E et al. (1994). Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330: 1267-1271.
106. Peng Z, Zhang Y, Gu W, Wang Z, Li D, Zhang F et al. (2005). Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis. Int J Oncol 26: 467-473.
107. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K et al. (2004). Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119: 529-542.
108. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al. (2004). NF-kappaB functions as a tumour promoter in inflammation- associated cancer. Nature 431: 461-466.
109. Prusty BK, Hedau S, Singh A, Kar P, Das BC. (2007). Selective suppression of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality. Mol Med 13: 518-526.
110. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. (2002). Cutting edge: impaired toll-like receptor expression and function in aging. J Immunol 169: 4697-4701.
111. Ribeiro PS, Cortez-Pinto H, Sola S, Castro RE, Ramalho RM, Baptista A et al. (2004). Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 99: 1708-1717.
112. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. (1997). Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276-1280.
113. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V et al. (2008). NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 453: 808-811.
114. Rogers AB, Theve EJ, Feng Y, Fry RC, Taghizadeh K, Clapp KM et al. (2007). Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res 67: 11536-11546.
115. Rothwarf DM, Karin M. (1999). The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999: RE1.
116. Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J et al. (2000). Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev 14: 854-862.
117. Saile B, DiRocco P, Dudas J, El-Armouche H, Sebb H, Eisenbach C et al. (2004). IGF-I induces DNA synthesis and apoptosis in rat liver hepatic stellate cells (HSC) but DNA synthesis and proliferation in rat liver myofibroblasts (rMF). Lab Invest 84: 1037-1049.
118. Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. (2001). Thebcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol 80: 554-561.
119. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G et al. (2008). Hepatocyte necrosis induced by oxidative stress and IL-1a release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14: 156-165.
120. Sakurai T, Maeda S, Chang L, Karin M. (2006). Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103: 10544-10551.
121. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. (1993). Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 90: 7240-7244.
122. Sato Y, Kato J, Takimoto R, Takada K, Kawano Y, Miyanishi K et al. (2006). Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut 55: 1801-1808.
123. Scheidereit C. (2006). IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. Oncogene 25: 6685-6705.
124. Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, Schoonhoven R et al. (2003). c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology 37: 824-832.
125. Schwabe RF, Seki E, Brenner DA. (2006). Toll-like receptor signaling in the liver. Gastroenterology 130: 1886-1900.
126. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA et al. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13: 1324-1332.
127. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G et al. (2001). Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293: 1495-1499.
128. Smith WL, Garavito RM, DeWitt DL. (1996). Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160.
129. Solnick JV, Schauer DB. (2001). Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 14: 59-97.
130. Stanley J, Linton D, Burnens AP, Dewhirst FE, On SL, Porter A et al. (1994). Helicobacter pullorum sp. nov.-genotype and phenotype of a new species isolated from poultry and from human patients with gastroenteritis. Microbiology 140(Part 12): 3441-3449.
131. Stein M, Rappuoli R, Covacci A. (2000). Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci USA 97: 1263-1268.
132. Su F, Schneider RJ. (1996). Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol 70: 4558-4566.
133. Suerbaum S, Josenhans C, Claus H, Frosch M. (2002). Bacterial genomics: seven years on. Trends Microbiol 10: 351-353.
134. Suetsugu H, Iimuro Y, Uehara T, Nishio T, Harada N, Yoshida M et al. (2005). Nuclear factor {kappa}B inactivation in the rat liver ameliorates short term total warm ischaemia/reperfusion injury. Gut 54: 835-842.
135. Sun SC, Ganchi PA, Ballard DW, Greene WC. (1993). NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 259: 1912-1915.
136. Sung JJ, Leung WK, Go MY, To KF, Cheng AS, Ng EK et al. (2000). Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 157: 729-735.
137. Sunitha S, Nagaraj M, Varalakshmi P. (2001). Hepatoprotective effect of lupeol and lupeol linoleate on tissue antioxidant defence system in cadmium-induced hepatotoxicity in rats. Fitoterapia 72: 516-523.
138. Szabo G, Mandrekar P. (2002). Ethanol-mediated regulation of transcription factors in immunocompetent cells. Front Biosci 7: a80-a89.
139. Tai DI, Tsai SL, Chen YM, Chuang YL, Peng CY, Sheen IS et al. (2000). Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 31: 656-664.
140. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. (2004). Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23: 9247-9258.
141. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T et al. (1999). Limb and skin abnormalities in mice lacking IKKalpha. Science 284: 313-316.
142. Tanaka K, Nagao Y, Ide T, Kumashiro R, Sata M. (2006). Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study. Int J Mol Med 17: 827-832.
143. Tang W, Lazaro CA, Campbell JS, Parks WT, Katze MG, Fausto N. (2007). Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame. Am J Pathol 171: 1831-1846.
144. Thumann C, Schvoerer E, Abraham JD, Bohbot A, Stoll-Keller F, Aubertin AM et al. (2008). Hepatitis C virus structural proteins do not prevent human dendritic cell maturation. Gastroenterol Clin Biol 32: 59-68.
145. Tiegs G, Hentschel J, Wendel A. (1992). A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90: 196-203.
146. Tissing WJ, Meijerink JP, den Boer ML, Pieters R. (2003). Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia 17: 17-25.
147. Toledo LP, Ong TP, Pinho AL, Jordao Jr A, Vanucchi H, Moreno FS. (2003). Inhibitory effects of lutein and lycopene on placental glutathione S-transferase-positive preneoplastic lesions and DNA strand breakage induced in Wistar rats by the resistant hepatocyte model of hepatocarcinogenesis. Nutr Cancer 47: 62-69.
148. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD et al. (1997). The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388: 539-547.
149. Trejo-Avila L, Elizondo-Gonzalez R, Trujillo-Murillo Kdel C, Zapata-Benavides P, Rodriguez-Padilla C, Rivas-Estilla AM. (2007). Antiviral therapy: inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the viral genome. Ann Hepatol 6: 174-180.
150. Tsujii M, Kawano S, DuBois RN. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340.
151. Turini ME, DuBois RN. (2002). Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53: 35-57.
152. Uchinami H, Yamamoto Y, Kume M, Yonezawa K, Ishikawa Y, Taura K et al. (2002). Effect of heat shock preconditioning on NFkappaB/I-kappaB pathway during I/R injury of therat liver. Am J Physiol Gastrointest Liver Physiol 282: G962-G971.
153. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al. (2001). Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789.
154. Um HR, Lim WC, Chae SY, Park S, Park JH, Cho H. (2007). Raf-1 and protein kinase B regulate cell survival through the activation of NF-kappaB in hepatitis B virus X-expressing cells. Virus Res 125: 1-8.
155. Umemura T, Kai S, Hasegawa R, Kanki K, Kitamura Y, Nishikawa A et al. (2003). Prevention of dual promoting effects of pentachlorophenol, an environmental pollutant, on diethylnitrosamine-induced hepato- and cholangiocarcinogenesis in mice by green tea infusion. Carcinogenesis 24: 1105-1109.
156. Vergani D, Mieli-Vergani G. (2004). Autoimmune hepatitis. Minerva Gastroenterol Dietol 50: 113-123.
157. Wahl C, Liptay S, Adler G, Schmid RM. (1998). Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101: 1163-1174.
158. Ward JM, Anver MR, Haines DC, Benveniste RE. (1994a). Chronic active hepatitis in mice caused by Helicobacter hepaticus. Am J Pathol 145: 959-968.
159. Ward JM, Fox JG, Anver MR, Haines DC, George CV, Collins Jr MJ et al. (1994b). Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst 86: 1222-1227.
160. Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A. (2003). Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. J Biol Chem 278: 40778-40787.
161. Waris G, Siddiqui A. (2003). Regulatory mechanisms of viral hepatitis B and C. J Biosci 28: 311-321.
162. Waris G, Tardif KD, Siddiqui A. (2002). Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem Pharmacol 64: 1425-1430.
163. Weil R, Sirma H, Giannini C, Kremsdorf D, Bessia C, Dargemont C et al. (1999). Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol 19: 6345-6354.
164. Wiegand J, Mossner J, Tillmann HL. (2008). Diagnostics and therapy of chronic hepatitis B and C. Internist (Berl) 49: 817-829.
165. Williams CS, Smalley W, DuBois RN. (1997). Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 100: 1325-1329.
166. Wong CM, Ng IO. (2008). Molecular pathogenesis of hepatocellular carcinoma. Liver Int 28: 160-174.
167. Yamada Y, Kirillova I, Peschon JJ, Fausto N. (1997). Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci USA 94: 1441-1446.
168. Yan M, Kuang X, Scofield VL, Shen J, Lynn WS, Wong PK. (2007). The glucocorticoid receptor is increased in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells, and its nuclear translocation counteracts c-myc expression. Steroids 72: 415-421.
169. Yin M, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM et al. (2001). Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol 166: 4737-4742.
170. Young VB, Chien CC, Knox KA, Taylor NS, Schauer DB, Fox JG. (2000a). Cytolethal distending toxin in avian and human isolates of Helicobacter pullorum. J Infect Dis 182: 620-623.
171. Young VB, Knox KA, Schauer DB. (2000b). Cytolethal distending toxin sequence and activity in the enterohepatic pathogen Helicobacter hepaticus. Infect Immun 68: 184-191.
172. Yun C, Um HR, Jin YH, Wang JH, Lee MO, Park S et al. (2002). NF-kappaB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Cancer Lett 184: 97-104.
173. Zarrilli R, Ricci V, Romano M. (1999). Molecular response of gastric epithelial cells to Helicobacter pylori-induced cell damage. Cell Microbiol 1: 93-99.
174. Zhao CY, Wang JB, Deng ZJ, Liu JW, Li JM, Li L et al. (2005). Relationship between NF-kappa B binding activity and expression of PPAR gamma-mRNA in the livers of rats with fatty liver disease. Zhonghua Gan Zang Bing Za Zhi 13: 96-100.
175. Zimmermann M, Flechsig C, La Monica N, Tripodi M, Adler G, Dikopoulos N. (2008). Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes. J Hepatol 48: 51-60.